[Form 4] NEOGEN CORP Insider Trading Activity

Rhea-AI Filing Summary

Neogen Corporation Senior Vice President Tamara A. Ranalli reported new equity awards. On January 7, 2026, she was granted 130,605 options to acquire Neogen common stock at an exercise price of $7.38 per share, leaving her with 130,605 derivative securities beneficially owned directly. The same day she also acquired 50,813 shares of common stock at a stated price of $7.38 per share, bringing her directly held common stock to 50,813 shares. According to the filing, the options and restricted stock units vest in three equal annual installments on each of the first three anniversaries of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ranalli Tamara A.

(Last) (First) (Middle)

620 LESHER PLACE

(Street)

LANSING MI 48912

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEOGEN CORP [ NEOG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		A		50,813(1)	A	$7.38	50,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (Right to Buy)	$7.38	01/07/2026		A		130,605		(1)	01/07/2036	Common Stock	130,605	$0	130,605	D

Explanation of Responses:

1. Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants

	Christopher Sefcheck (Attorney in Fact)	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Neogen (NEOG) report for Tamara A. Ranalli?

Neogen reported that Senior Vice President Tamara A. Ranalli received new equity awards on January 7, 2026, including options and common stock, which increased her directly held stake in the company.

How many Neogen (NEOG) stock options were granted to Tamara A. Ranalli?

Tamara A. Ranalli was granted 130,605 options with a right to buy Neogen common stock at an exercise price of $7.38 per share, and she beneficially owns all 130,605 derivative securities directly after the grant.

How many Neogen (NEOG) common shares did Tamara A. Ranalli acquire in this Form 4?

She acquired 50,813 shares of Neogen common stock at a stated price of $7.38 per share, resulting in 50,813 common shares directly beneficially owned following the transaction.

What is the vesting schedule for Tamara A. Ranalli’s Neogen equity awards?

The filing states that her options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grant date.

Does Tamara A. Ranalli hold Neogen (NEOG) securities directly or indirectly?

According to the report, both the 130,605 options and the 50,813 common shares are held with direct beneficial ownership.

What position does Tamara A. Ranalli hold at Neogen (NEOG)?

She is reported as an officer of Neogen Corporation with the title Senior Vice President.